

Top 20 Series: Rank 6: Bharat Serums and Vaccines Ltd: A year of robust growth

13 October 2015 | News | By BioSpectrum Bureau

Top 20 Series: Rank 6: Bharat Serums and Vaccines Ltd: A year of robust growth



Organization: Bharat Serums and Vaccines Ltd

CMD: Mr Bharat Daftary

Bioscience Revenue: Rs 565 crore

During the fiscal year 2014-15, the bioscience revenue for Bharat Serums and Vaccines (BSV) stood at Rs 565 crore, a growth of 32 percent from Rs 428 in the FY 2013-14. Founded in 1971, Mumbai-based BSV is one of the leading player in the area of biologics.

The company focus on the research, development, manufacturing and marketing of specialized biological, pharmaceutical and biotechnology products that combat disease and enhance quality of life. It has three R&D centers located in India, Germany, and USA.

The company also has a horse farm for production of equine anti-sera and anti-toxins. Its brands are marketed all over India and exported to over 45 countries across the world.

In the FY 2014-15, the company received marketing approval for the world's first monoclonal tetanus immunoglobulin, mTIG.

The other key development is the successful completion of a bioequivalence study for one its fertility drugs in comparison with the innovator, bringing the firm closer to a potential worldwide approval in targeted markets.

The other major development includes receiving an EU orphan drug designation for its biopharmaceutical molecules to treat severe acute pancreatitis. The company claims that it is possibly the first Indian company to receive this designation. The company also observed promising growth in its international market business.

In the FY 2015-16, BSV is focusing on partnering and developing some of its biopharmaceutical molecules for eventual launch in the US and Europe. It is also identifying key emerging market countries with emphasis on our biopharmaceutical portfolio and expansion of its sales and marketing efforts. The company is also eyeing expansion of the domestic market with its recently launched molecules.

More recently Gujarat-based drug maker Cadila Healthcare Ltd, which runs under the brand Zydus Cadila, has acquired entire 50 per cent stake in Zydus BSV Pharma Pvt Ltd from its JV partner Bharat Serums and Vaccines Ltd. Post this acquisition, Zydus BSV has become a wholly-owned subsidiary of Cadila Healthcare.

The company focuses on the niche segment of targeted therapies in oncology. It develops, manufactures and markets novel drug delivery system of anti-cancer agents for global markets. Zydus BSV has a finished dosage manufacturing plant in Ahmadabad. Mumbai-based Bharat Serums and Vaccines, which was founded in 1971, manufactures and markets pharma and biotechnology products.